Compare CTRA & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTRA | DGX |
|---|---|---|
| Founded | 1989 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.6B | 23.1B |
| IPO Year | 1994 | 1996 |
| Metric | CTRA | DGX |
|---|---|---|
| Price | $33.36 | $195.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | $34.79 | ★ $208.62 |
| AVG Volume (30 Days) | ★ 9.1M | 660.7K |
| Earning Date | 05-04-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.63% | 1.76% |
| EPS Growth | ★ 49.33 | 13.78 |
| EPS | 2.24 | ★ 8.75 |
| Revenue | $7,645,000,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $10.48 | $7.55 |
| Revenue Next Year | $9.28 | $3.75 |
| P/E Ratio | ★ $14.89 | $22.38 |
| Revenue Growth | ★ 40.07 | 11.78 |
| 52 Week Low | $22.33 | $157.20 |
| 52 Week High | $33.44 | $213.50 |
| Indicator | CTRA | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 70.69 | 40.87 |
| Support Level | $23.03 | $176.61 |
| Resistance Level | N/A | $197.55 |
| Average True Range (ATR) | 0.85 | 4.21 |
| MACD | 0.13 | -1.78 |
| Stochastic Oscillator | 97.58 | 5.10 |
Coterra Energy Inc is an independent oil and gas company engaged in the development, exploration, and production of oil, natural gas, and natural gas liquids (NGLs). Its operations are mainly concentrated in areas with hydrocarbon resources, which are conducive to multi-well, repeatable development programs, and include the Permian Basin located in Texas and New Mexico, the Marcellus Shale in northeast Pennsylvania, and the Anadarko Basin located in the mid-continent region in Oklahoma. The company operates in one segment, oil and natural gas development, exploration, and production, in the continental U.S.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.